Adial Pharmaceuticals (ADIL) vs Phio Pharmaceuticals (PHIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adial Pharmaceuticals (ADIL) has outperformed Phio Pharmaceuticals (PHIO) over the past year, losing 59.1% versus a loss of 59.8%. Over five years, PHIO leads with a -99.4% price change compared with -99.8% for ADIL. Phio Pharmaceuticals is the larger company by market cap ($11.3 million vs $10.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADIL | PHIO |
|---|---|---|
| Share price | $3.97 | $0.9731 |
| Market cap | $10.42M | $11.30M |
| 1-day change | -0.50% | -2.69% |
| YTD return | -27.45% | -7.32% |
| 1-year return | -59.08% | -59.79% |
| 5-year return | -99.84% | -99.45% |
| EPS (TTM) | $-20.65 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.75 | $4.19 |
| 52-week low | $1.31 | $0.813 |
| Distance from 52-week high | -63.07% | -76.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.82% | +1338.70% |
| Average volume | 56.77K | 584.05K |
| Shares outstanding | 2.63M | 11.62M |
| Employees | 5 | 6 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adial Pharmaceuticals
ADIL stock →Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Healthcare · Biotechnology · 5 employees
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Healthcare · Biotechnology · 6 employees
ADIL vs PHIO FAQ
Which is bigger, Adial Pharmaceuticals or Phio Pharmaceuticals?
Phio Pharmaceuticals (PHIO) is larger, with a market capitalization of $11.30M compared with $10.42M for Adial Pharmaceuticals (ADIL).
Which stock has performed better over the past year, ADIL or PHIO?
ADIL returned -59.08% over the past 12 months, compared with -59.79% for PHIO (price return, excluding dividends). Past performance does not predict future results.
Are Adial Pharmaceuticals and Phio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.